Opioid toxidrome
Formal Definition
A clinical toxidrome resulting from acute or chronic exposure to opioid receptor agonists (heroin, fentanyl, morphine, oxycodone, methadone, buprenorphine, etc.) causing CNS and respiratory depression — the classic triadic presentation includes CNS depression (decreased level of consciousness ranging from somnolence to coma), respiratory depression (decreased respiratory rate and tidal volume, often with classic central cyanosis), and miosis (pupillary constriction with pinpoint pupils); supportive findings include bradycardia, hypotension, hypothermia, decreased bowel sounds, needle track marks or other injection evidence, and response to naloxone administration.
How It's Used on the Ward
"Opioid toxidrome" or "the typical ODs" — the patient comes in with pinpoint pupils, barely breathing, and down for the count — classic opioid overdose; treatment is naloxone (Narcan) IV or intranasal, supportive ventilation, and frequent reassessment because naloxone wears off faster than most long-acting opioids.
Example
""22-year-old found unresponsive at home with multiple needle track marks and a fentanyl patch nearby; friend reports the patient used heroin earlier in the day. EMS: RR 4, HR 52, BP 88/56, SpO2 78%, GCS 4, pinpoint pupils. EMS administered intranasal naloxone 4mg with partial response — RR increased to 12, GCS improved to 12 but still drowsy. ED: continued naloxone drip at 2 mg/h, oxygen supplementation, monitoring. Toxicology workup including screening for additional ingestions (co-ingestion with benzodiazepines or stimulants common). Disposition depends on response; naloxone drip continued for several hours due to recurrent sedation; admission for monitoring.""
Clinical Context
Pharmacology behind the toxidrome: opioids bind mu-opioid receptors (primarily) in CNS causing analgesia, sedation, respiratory depression, miosis; kappa-opioid receptors contribute to miosis and respiratory effects; delta receptors modulate analgesia. Reversal agent: naloxone — competitive opioid antagonist with rapid onset (1-2 min IV, 2-5 min IM/intranasal), short half-life (~30-90 min) — much shorter than most opioids, so re-dosing or continuous infusion needed for long-acting agents (methadone, fentanyl). Naloxone dosing: start low (0.04-0.1 mg IV) for chronic users in pain management to avoid precipitating severe withdrawal; higher doses (0.4-2 mg IV or 2-4 mg intranasal) for community overdose reversal. Risks of naloxone: precipitating opioid withdrawal (severe in chronic users — body aches, vomiting, diarrhea, agitation); unmasking concomitant drug effects (if co-ingested with stimulants, naloxone unmasks sympathetic effects); aspiration if patient vomits. ICU consideration: for severe opioid overdose (especially with prolonged respiratory arrest, hypoxic injury, brain anoxia), supportive care in ICU is critical. Bystander naloxone (Narcan) availability has dramatically reduced opioid mortality.